Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
May 14, 2024 10:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 08, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
March 14, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
March 05, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
January 29, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
January 09, 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 03, 2024 21:29 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros Therapeutics Announces Proposed Public Offering of Common Stock
January 03, 2024 16:05 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
January 03, 2024 08:00 ET
|
Keros Therapeutics, Inc.
Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report...